Coherus and AbbVie settle Humira biosimilar dispute after Mark Cuban’s Cost Plus Drugs announcement

Biosimilars player Coherus Biosciences has patched things up with AbbVie after the pharma said Coherus violated its non-exclusive license to commercialize Yusimry, a biosimilar of Humira, a rheumatoid arthritis drug.

On June 6, Coherus received a notice from AbbVie because of Coherus’ announcement on June 1 of its pricing agreement with Mark Cuban Cost Plus Drug Company and its plans to offer Yusimry to Cost Plus Drugs customers beginning in July, according to SEC filings.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Thousands of Kids Prescribed ‘Potentially Harmful’ Drugs for Acute COVID

Clinicians prescribed hydroxychloroquine (HCQ) and ivermectin inappropriately to thousands of children with acute COVID-19, according to a retrospective cohort study. In a large U.S. all-payer

May 10, 2024

Animal rights group urges SEC to investigate Charles River over monkey purchases

A leading animal rights group has asked securities regulators to investigate Charles River Laboratories for allegedly misleading investors about its sales and purchases of long-tailed

April 18, 2024

Here Are the Top 7 Psychedelic Retreats in Mexico

Mexico, with its vibrant culture, breathtaking landscapes, and deep spiritual traditions, has become a sought-after destination for those seeking profound inner experiences through psychedelic retreats.

June 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.